Showing results (1161-1170 of 4,514) with videos related to
Sort By:
Pageof 452
Future Oncology (London, England)|July 14, 2010
Aptamer applications for targeted cancer therapyAndrew S Barbas, Jing Mi, Bryan M Clary, et al.Future Oncology (London, England)|March 23, 2011
Current appraisal of conjunctival melanocytic tumors: classification and treatmentHooman Harooni, Lynn R Schoenfield, Arun D SinghFuture Oncology (London, England)|April 6, 2011
Notch regulation of tumor angiogenesisEsther Bridges, Chern Ein Oon, Adrian HarrisFuture Oncology (London, England)|May 30, 2019
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemiaAnna M Frustaci, Alessandra Tedeschi, Marina Deodato, et al.Future Oncology (London, England)|May 23, 2019
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancerBernardo Rapoport, Ramin B Arani, Nicola Mathieson, et al.Future Oncology (London, England)|June 5, 2019
Extracting data from a chemotherapy prescription platform for real-world oncology research in the UK: a pilot studyLaura McDonald, Dara Stein, Robert Carroll, et al.Future Oncology (London, England)|August 12, 2016
The next generation of novel therapies for the management of relapsed multiple myelomaWilson I Gonsalves, Paolo Milani, Daniel Derudas, et al.Future Oncology (London, England)|July 15, 2020
Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutationFumio Imamura, Madoka Kimura, Yukihiro Yano, et al.Future Oncology (London, England)|July 16, 2020
Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trialCharlien Berghen, Steven Joniau, Annouschka Laenen, et al.Future Oncology (London, England)|July 18, 2020
How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancerCengiz Karacin, Irem Bilgetekin, Fatma B Basal, et al.Pageof 452